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A B S T R A C T
The genetically diverse Orthocoronavirinae (CoV) family is prone to cross species transmission and disease
emergence in both humans and livestock. Viruses similar to known epidemic strains circulating in wild and
domestic animals further increase the probability of emergence in the future. Currently, there are no approved
therapeutics for any human CoV presenting a clear unmet medical need. Remdesivir (RDV, GS-5734) is a
monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus fa-
milies including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the
viral RNA dependent RNA polymerase (RdRp). We developed multiple assays to further define the breadth of
RDV antiviral activity against the CoV family. Here, we show potent antiviral activity of RDV against endemic
human CoVs OC43 (HCoV-OC43) and 229E (HCoV-229E) with submicromolar EC50 values. Of known CoVs, the
members of the deltacoronavirus genus have the most divergent RdRp as compared to SARS- and MERS-CoV and
both avian and porcine members harbor a native residue in the RdRp that confers resistance in beta-CoVs.
Nevertheless, RDV is highly efficacious against porcine deltacoronavirus (PDCoV). These data further extend the
known breadth and antiviral activity of RDV to include both contemporary human and highly divergent zoonotic
CoV and potentially enhance our ability to fight future emerging CoV.
1. Introduction
The genetically diverse Orthocoronavirinae (CoV) family is divided
into four genera (alpha, beta, gamma, and deltacoronavirus) and thus far
human CoV are limited to the alpha and beta genera. Human CoVs
OC43, 229E, NL63 and HKU1 cause 10% of all upper and lower re-
spiratory tract infections, which typically present with common-cold
like symptoms but can cause more severe disease in young children as
well as people with underlying respiratory conditions (i.e. asthma,
COPD) and the elderly (Dijkman et al., 2012; Falsey et al., 2002). In
children, severe respiratory tract CoV infections require hospitalization
in about 10% of cases and have been associated with febrile seizure in
those less than 1 year old (Carman et al., 2018; Heimdal et al., 2019).
CoV infection can also be severe in the elderly requiring hospitalization
and can even cause acute respiratory distress syndrome (ARDS) (Falsey
et al., 2002; Vassilara et al., 2018). Zoonotic CoVs have a natural pre-
dilection for emergence into new host species giving rise to new dis-
eases most recently exemplified in humans by severe acute respiratory
syndrome coronavirus (SARS-CoV), and Middle East respiratory syn-
drome coronavirus (MERS-CoV) (de Wit et al., 2016). Interestingly, all
known human CoVs are thought to have emerged as zoonoses from wild
or domestic animals (Hu et al., 2015a; Huynh et al., 2012; Menachery
et al., 2016; Vijgen et al., 2005). This emergence paradigm is not un-
ique to human CoVs. Novel animal CoVs like porcine epidemic diarrhea
virus (PEDV), porcine delta coronavirus (PDCoV) and swine acute
diarrhea syndrome coronavirus (SADS-CoV) have recently emerged
causing the deaths of millions of piglets and billions of dollars in
agricultural losses (Hu et al., 2015b; Huang et al., 2013; Zhou et al.,
2018). While chloroquine, ribavirin, lopinavir and interferons have all
been tested against multiple CoV in vitro, currently, there are no
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2.2. Remdesivir (RDV)
RDV was synthesized at Gilead Sciences Inc. (Siegel et al., 2017) and
its chemical identity and purity were determined by nuclear magnetic
resonance, high-resolution mass spectrometry, and high-performance
liquid chromatography (HPLC) analysis. RDV was made available to the
University of North Carolina at Chapel Hill (UNC) under a material
transfer agreement with Gilead Sciences. RDV was solubilized in 100%
DMSO for in vitro studies.
2.3. HCoV-OC43 antiviral focus forming assay in Huh7 cells
Poly-L Lysine (Gibco, ThermoFisher Scientific) coated 96-well plates
were seeded with 2E+05 Huh7 cells/well. The following day, cells
were infected with HCoV-OC43 (MOI = 0.025) diluted in “infection
medium” (DMEM, 5% FBS, anti/anti, all ThermoFisher Scientific) in the
presence of DMSO or a dose response of RDV for 1 h at 32 °C. After 1 h,
cells were overlaid with Optimem (Gibco, ThermoFisher Scientific), 1%
carboxymethyl cellulose, 2% FBS, NEAA, anti/anti that contained
DMSO or the dose response of RDV. Final DMSO concentration was held
at 0.05% in all conditions. Four to eight replicate wells were allotted to
each condition. Non-infected cells treated with DMSO were also in-
cluded as a “100% inhibition” control. After 72 h treatment at 32 °C,
cells were fixed in 10% buffered formalin (ThermoFisher Scientific),
permeabilized with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO),
blocked in PBS 1% BSA/0.2% skim milk and the endogenous peroxidase
was quenched with 3% hydrogen peroxide (ThermoFisher Scientific).
OC43 antigen was stained with antibody (primary: mouse anti-OC43
nucleoprotein antibody (Millipore MAB9013), secondary: goat anti-
mouse HRP antibody (KPL 474–1806)) and visualized with DAB re-
agent (ThermoFisher Scientific). Infected cell foci were visualized and
quantitated via CTL ImmunoSpot ELIspot reader (CTL, Cleveland, OH,
USA). The effective concentration that reaches 50% decrease in viral
replication was defined as the EC50 value. The EC50 value was calcu-
lated from a dose-response curve using 4-parameter (variable slope)
equation (Equation (1)) in GraphPad Prism 8 (GraphPad).
Y = 100/(1 + 10^((LogEC50-X)*HillSlope)) (1)
Where Y represents % of inhibition and X represents RDV concentra-
tion. Mock infected cells were used as control for 100% inhibition and
cells treated with vehicle alone was used as control for 0% inhibition.
2.4. HCoV-OC43 antiviral fluorescence in situ hybridization (FISH)
imaging assay
In a 12-well plate, calf skin collagen (Sigma-Aldrich, St. Louis, MO)
coated glass cover slips (18 mm round #1, Neuvitro, ThermoFisher
Scientific) were seeded with 2E+05 Huh7 cells/well 24 h prior to in-
fection. Cells were infected with HCoV-OC43 (MOI = 0.025) diluted in
“infection medium” containing either 0.25, 0.1, 0.025 or 0.01 μM RDV
or DMSO vehicle control for 1 h at 32 °C. After 1 h, monolayers were
washed and infection medium containing the previously described
DMSO or RDV was added. After 6 days at 32 °C, coverslips were fixed
with 3.7% formaldehyde in PBS for 10 min, washed with PBS and
stored in 70% ethanol until staining. 48 unique oligonucleotide probes
against ORF1a coupled with Quasar 570 were fabricated by LGC
Biosearch Technologies. Fixed coverslips were FISH stained and nuclei
were counterstained with Hoechst 33258 (ThermoFisher Scientific)
according to the protocol provided by LGC. Coverslips were imaged on
a Keyence BZX-700 automated microscope. Images were acquired with
the same settings and cell quantitation was performed using the
Keyence Hybrid Cell Count analysis package (Matsuda et al., 2018).
approved therapeutics for any human CoV (Chan et al., 2013; de Wilde 
et al., 2014; Shen et al., 2016). To address an unmet medical need for 
the treatment of current human CoV infections and to maximize pan-
demic preparedness, broad spectrum antiviral therapies are needed that 
are effective against current and future emerging CoV given the nu-
merous examples of novel CoV emergence.
Remdesivir (RDV, GS-5734) is a monophosphoramidate prodrug of 
an adenosine analog with demonstrated antiviral activity against an 
array of RNA virus families including Filoviridae, Paramyxoviridae, 
Pneumoviridae, and CoV (Lo et al., 2017; Sheahan et al., 2017; Warren 
et al., 2016). The antiviral mechanism for RDV has been demonstrated 
to be through delayed chain termination of nascent viral RNA of for 
Ebola virus, Nipah virus and respiratory syncytial virus (Jordan et al., 
2018; Lo et al., 2017; Tchesnokov et al., 2018, 2019; Warren et al., 
2016). We previously reported the antiviral activity of RDV against a 
genetically diverse panel of human endemic, emerging and zoonotic 
CoV including HCoV-NL63 (alpha 1b), mouse hepatitis virus (MHV, 
beta 2a), SARS-CoV and related Bat CoVs WIV1 and SHC014 (beta 2b), 
as well as MERS-CoV and related Bat CoV HKU5 (beta 2c) (Agostini 
et al., 2018; Sheahan et al., 2017). Upon passage of MHV in the pre-
sence of RDV, resistance mutations arise in the RNA dependent RNA 
polymerase (RdRp) that confer resistance (i.e. up to a 5-fold shift in 
EC50) demonstrating that the RdRp is a target of RDV antiviral activity 
(Agostini et al., 2018). The CoV RdRp is highly conserved within gen-
ogroups (i.e. beta 2b) but amino acid identity between groups varies 
from 70 to 90% (Sheahan et al., 2017). Here, we expand upon our 
earlier work to better understand the spectrum of RDV efficacy among 
human and zoonotic CoV. We show that RDV inhibits endemic human 
CoVs 229E and OC43 as well as a member of the deltacoronavirus genus, 
PDCoV, which have the most divergent RdRp of known CoV as com-
pared to SARS- and MERS-CoV. These data further illuminate the 
breadth and antiviral activity of RDV against the CoV family and sug-
gest RDV as a potential antiviral for current endemic and epidemic CoV 
as well as future emerging CoV.
2. Materials and methods
2.1. Viruses and cells
Human colorectal carcinoma (HCT-8, CCL-244) cells were pur-
chased from American Type Culture Collection (ATCC, Manassas, VA) 
and maintained in RPMI-1640 (ThermoFisher Scientific), 10% fetal 
bovine serum (FBS, Hyclone, ThermoFisher Scientific) and antibiotic/
antimycotic (anti/anti, Gibco, ThermoFisher Scientific). Human hepa-
toma (Huh7) cells were kindly provided by Dr. Mark Heise at UNC 
Chapel Hill. Huh7 cells were grown in Dulbecco's Modified Eagle's 
Medium (DMEM, Gibco, ThermoFisher Scientific), 10% FBS (Hyclone) 
and anti/anti (Gibco, ThermoFisher Scientific). Porcine kidney (LLC-
PK1) cells were purchased from the UNC Tissue Culture Facility and 
maintained in DMEM, 5% Fetal Clone 2 (Hyclone, ThermoFisher 
Scientific), non-essential amino acids (NEAA, Gibco, ThermoFisher 
Scientific), 10 mM HEPES (Gibco, ThermoFisher Scientific), anti/anti 
(Gibco, ThermoFisher Scientific). Human lung fibroblast (MRC5) cells 
were purchased from ATCC (CCL-171) and maintained in MEM (Gibco), 
10% FBS (Hyclone, ThermoFisher Scientific) and anti/anti (Gibco, 
ThermoFisher Scientific). The VR-1558 strain of HCoV-OC43 was pur-
chased from ATCC, passaged once on HCT-8 cells and amplified once on 
Huh7 cells to create a working stock. The VR-740 strain of HCoV-229E 
was purchased from ATCC, passaged once on MRC5 cells and amplified 
once on Huh7 cells to create a working stock. Porcine deltacoronavirus 
(PDCoV) strain OH-FD22 LLCPK P5 was kindly provided by Dr. Linda 
Saif at Ohio State University. PDCoV virus stock was created through 
passage on LLC-PK1 cells in Optimem (Gibco, ThermoFisher Scientific), 
NEAA (Gibco, ThermoFisher Scientific), 10 mM HEPES (Gibco, 
ThermoFisher Scientific), anti/anti (Gibco), 0.3% tryptose phosphate 
broth and 0.0025% pancreatin (Sigma-Aldrich, St. Louis, MO).
2.5. HCoV-OC43 genomic and subgenomic qRT-PCR assay
12-well plates of Huh7 cells were prepared without coverslips, in-
fected and treated similarly to those described for FISH. After 6 days,
total RNA was isolated via Qiagen RNeasy kit, quantified by NanoDrop
(Thermo) and stored at −80 °C until analysis. Previously published
TaqMan style “PrimeTime” qRT-PCR assays were generated by
Integrated DNA technologies (IDT) to measure genomic RNA (Orf1b,
All 5′-3′, Forward GTGGATTCTGCTCAAG, Probe (5′ 6-FAM/ZEN/3′
IBFQ) ATTCACAGACTGCAGAAACAGCGCATTCTGTA Reverse AATAC
CTTTCTTGGCTCGAGTAAT) and subgenomic RNA (Nucleocapsid, All
5′-3′, Forward CGATGAGGCTATTCCGACTAGGT, Probe (5′ 6-FAM/
ZEN/3′ IBFQ) TCCGCCTGGCACGGTACTCCCT, Reverse CTTCCTGAGC
CTTCAATATAGTAACC) (Loens et al., 2012; Walsh et al., 2013). Single
step qRT-PCR was performed using Fast Virus 1-Step Master Mix
(ThermoFisher Scientific) and associated program in a Roche Light
Cycler qPCR machine. Each reaction contained 100 ng of total RNA for
experimental samples. Copy number/reaction was generated using an
HCoV-OC43 RNA standard curve.
2.6. Cytopathic effect based HCoV-229E antiviral assay
The day prior to infection, black-walled clear-bottom 96-well plates
(Corning #3904) were seeded with 2E+05 Huh7 cells/well. Cells were
infected with HCoV-229E (MOI = 0.15) diluted in infection medium
(DMEM, 5% FBS, anti/anti) in the presence of DMSO or a dose response
of RDV and incubated 32 °C for 6 days. Eight replicate wells were al-
lotted to each concentration condition. DMSO was held constant in all
conditions at 0.05%. Non-infected cells treated with DMSO were also
included as a “100% inhibition” control. At the termination of the
assay, cytopathic effect (CPE) was measured in a luminometer
(Promega Glomax, Promega, Madison, WI) by CellTiter-Glo Assay
(Promega, Madison, WI).
2.7. Porcine deltacoronavirus (PDCoV) antiviral assay in LLCKP1 and
Huh7 cells
The day prior to infection, black-walled clear-bottom 96-well plates
(Corning, Kennebunk, ME) were seeded with 2E+05 LLC-PK1 cells/
well. Cells were infected with PDCoV (MOI = 0.025) diluted in “in-
fection medium” (DMEM, HEPES, NEAA, anti/anti, 0.3% tryptose
phosphate broth and 0.0025% pancreatin) in the presence of RDV
(10–0.0015 μM) or DMSO for 3 days at 37 °C. Eight replicate wells were
allotted to each concentration condition. Final DMSO concentration
was held constant at 0.05% in all conditions. Non-infected cells treated
with DMSO were also included as a “100% inhibition” control. At the
termination of the assay, CPE was measured in a luminometer
(Promega Glomax) by CellTiter-Glo Assay (Promega). We performed
similar antiviral assays with HCoV-229E in LLC-PK1 cells with the
following changes: cells were infected with HCoV-229E at an MOI of
0.15 in the presence of (10–0.0015 μM) or DMSO diluted in PDCoV
infection medium for 6 days at 32 °C. For Huh7-based PDCoV assay,
conditions were similar to the LLC-PK1-based assay but with the fol-
lowing changes: TPCK Trypsin at 1 μg/mL was used rather than pan-
creatin, and cells were infected with PDCoV at a MOI of 0.0006 (titer
was determined on Huh7 cells). We performed similar antiviral assays
with HCoV-229E in Huh7 cells using the same media conditions used
for PDCoV with the following changes: cells were infected with HCoV-
229E at a MOI of 0.15 for 6 days at 32 °C.
2.8. Assessing cytotoxicity with RDV treatment
To assess RDV cytotoxicity in Huh7 and LLC-PK1 cells, cells were
seeded and treated with DMSO or RDV (10–0.0015 μM) diluted in the
appropriate infection medium and concurrent with each antiviral assay
described above. At the termination of each assay, cytoxicity was
measured via CellTiter-Glo assay (Promega) read on a Promega lu-
minometer. CC50 value was defined by the concentration required to
reach 50% cell death and determined by fitting a dose-response to
Equation (1), where the EC50 value is replaced by the CC50 value, using
GraphPad Prism 8. Cell-free samples were used as 100% cytotoxic
controls and vehicle-only cells were used as 0% cytotoxic controls.
2.9. Coronavirus phylogenetic analysis
Multiple sequence alignments and phylogenetic trees were con-
structed using the Geneious Tree Builder in Geneious 9.1.3 (http://
www.geneious.com). Tree visualization, customization and sequence
identity heat map creation was performed in Evolview (www.
evolgenius.info/evolview). The accession numbers utilized for phylo-
genetic analysis were: alphacoronavirus (group 1a) PEDV (porcine epi-
demic diarrhea virus, NC_003436); alphacoronavirus (group 1b) HCoV-
229E (JX503060), HCoV-NL63 (JX504050); betacoronavirus (group 2a)
HCoV-OC43 (AY903460), HCoV-HKU1 (DQ415904), MHV (mouse he-
patitis virus, AY910861.1); betacoronavirus (group 2b) SARS-CoV
(AY278741), BtCoV-SHC014 (bat coronavirus SHC014, KC881005),
BtCoV-WIV1 (bat coronavirus WIV1, KF367457), BtCoV-HKU3 (bat
coronavirus HKU3, DQ22305); betacoronavirus (group 2c) BtCoV-HKU5
(bat coronavirus HKU5, NC_009020), MERS-CoV (JX869059); betacor-
onavirus (group 2d) HKU9 (bat coronavirus HKU9, EF065516); gam-
macoronavirus (group 3) AIBV (avian infectious bronchitis virus,
NC_001451); deltacoronavirus (group 4) PDCoV (KR265863), HKU12
(thrush coronavirus, FJ376621), HKU13 (munia coronavirus,
FJ376622), HKU16 (white-eye coronavirus, JQ065044), HKU17
(sparrow coronavirus JQ065045), HKU18 (magpie robin coronavirus,
JQ065046), HKU19 (night heron coronavirus, JQ065047), HKU20
(wigeon coronavirus, JQ065048), HKU21 (common moorhen cor-
onavirus, JQ065049).
3. Results
3.1. Remdesivir (RDV) is a potent antiviral against human coronavirus
OC43
The EC50 values of RDV have previously been reported for MERS-
CoV [0.03 μM in Calu-3 cells; 0.074 μM in primary human airway epi-
thelial cells (HAE)], SARS-CoV (0.069 μM in HAE), and MHV (0.03 μM
in DBT cells) (Agostini et al., 2018; Sheahan et al., 2017). We sought to
determine the EC50 values of RDV for HCoV-OC43 and HCoV-229E,
which typically cause upper respiratory infection in children but can
cause more severe lower respiratory infection in adults with underlying
respiratory conditions (i.e. asthma, COPD) and the elderly (Falsey et al.,
2002). Since HCoV-OC43 does not cause an overt cytopathic effect
(CPE) in Huh7 cells, we established a focus forming reduction assay
(FFRA) for HCoV-OC43 (Fig. 1A) in 96-well plates based on nucleo-
capsid antigen staining (Fig. 1B) and quantification via Elispot reader
for increased throughput (Fig. 1C). Among the numerous viral genomic
and subgenomic messenger RNAs and protein products generated
during CoV replication, the nucleocapsid viral messenger RNA and
protein are the most abundant. We consistently observed an RDV dose-
dependent reduction in HCoV-OC43 antigen foci (Fig. 1D and E). Si-
milarly, the EC50 (0.14, 0.17, 0.16 μM, mean= 0.15 μM, standard de-
viation=0.015) was highly consistent from experiment to experiment
(Fig. 1F). Importantly, the CC50 obtained in Huh7 cells was> 10 μM.
Thus, for this assay system, the selectivity index (SI = CC50/EC50)
was> 66. This assay is driven by the detection nucleocapsid, the most
abundant viral protein during CoV replication. Thus, the dynamic range
of detection is maximized due to our antibody and viral antigen pairing,
which may have been notably lower had we chosen to measure the
expression of a viral protein with lower expression (e.g. non-structural
protein 2) (Neuman et al., 2008). Conversely, due to the high abun-
dance of nucleocapsid mRNA, RDV may cause reductions in viral RNAs
that are not detectable in this assay until a certain threshold is achieved
that results in significant diminishment of nucleocapsid protein pro-
duction.
3.2. RNA FISH and qRT-PCR demonstrate RDV diminishes HCoV-OC43
viral RNA
We aimed to corroborate the protein-based FFRA data for HCoV-
OC43 with multiple viral RNA-based techniques. First, we employed an
RNA fluorescence in situ hybridization (FISH) microscopy-based
Fig. 1. HCoV-OC43 Focus forming antiviral assay. A) HCoV-OC43 antiviral assay plate layout in Huh7 cells treated with DMSO or a dose response of RDV. B) A
dose dependent reduction in viral foci is visualized through antibody staining. C) The numbers of foci are quantitated on an ImmunoSpot Elispot reader to generate %
inhibition values. D) Example foci from a complete dose response of RDV. E) The quantitated number of spots per well for three independent experiments (A, B, C).
Each dot represents the data from one well in a multiwell plate. The line is drawn at the mean and error bars represent the standard deviation. F) EC50 values were
generated through graphing the percent inhibition from the above data in Graphpad Prism 8.
technique. The HCoV-OC43 ORF1a region of the genomic RNA was
stained with 48 unique oligonucleotide probes conjugated to a Quasar
570 fluorophore. With RNA FISH visualized through fluorescence mi-
croscopy, we observed an RDV dose-dependent reduction in HCoV-
OC43 genomic RNA (Fig. 2A). To quantify this trend, cell number in
three random microscopy fields per drug condition was determined by
automated enumeration of Hoechst stained nuclei along with the total
HCoV-OC43 FISH area/field (Fig. 2B). The number of nuclei per
random field were consistent among drug conditions (Fig. 2C). Simi-
larly, we observed more than a 5-log difference in HCoV-OC43 FISH
area comparing mock and infected cells in the absence of RDV. At the
highest dose of RDV (0.25 μM), HCoV-OC43 FISH signal was not de-
tected but as RDV dose was diminished, virus replication gradually
increased to levels similar to that in untreated cells (Fig. 2C). Similar
data were generated from concurrent and equivalent studies by quan-
titative reverse transcriptase PCR (qRT-PCR) measuring both genomic
(ORF1b) and subgenomic (nucleocapsid) viral RNA species. Due to the
increased sensitivity of PCR-based assays over microscopy, the dynamic
range of the qRT-PCR assay was more than 6 logs when comparing
mock to infected replicates (Fig. 2D). Similar to FISH, levels of HCoV-
OC43 genomic and subgenomic RNA treated with 0.25 μM RDV were
similar to that of mock infected and increased in an RDV dose depen-
dent manner. The resultant EC50 (0.02 μM) generated from the genomic
RNA assay was 7.5-fold lower than that obtained by FFRA but this is not
unexpected given the increased sensitivity of PCR-based assays. It is
important to note that our qPCR assay may be underestimating the
potency of RDV. The antiviral effect of RDV has been reported to be
through delayed chain termination (Jordan et al., 2018; Lo et al., 2017;
Tchesnokov et al., 2018, 2019; Warren et al., 2016). Thus, our assay
should detect both functional and non-functional truncated defective
viral RNAs as long as the target sequence is present.
3.3. Potent antiviral activity of RDV against human coronavirus 229E
Unlike HCoV-OC43, HCoV-229E infection of Huh7 causes CPE.
Thus, we established a CPE and CellTiter-Glo-based antiviral assay for
HCoV-229E (Fig. 3A). An RDV dose-dependent reduction in HCoV-229E
replication was observed (Fig. 3B) without drug-induced cytotoxicity
Fig. 2. RNA FISH and qRT-PCR demonstrate RDV diminishes HCoV-OC43 viral RNA. (A) Photomicrographs of HCoV-OC43 genomic RNA fluorescence in situ
hybridization (FISH). Huh7 infected with HCoV-OC43 at an MOI of 0.025 treated with dilutions of RDV or DMSO. Cell nuclei were counterstained with Hoechst. The
bar is 100 μM. Representative pictures from two independent experiments are shown. (B) Quantitation of RNA FISH signal through the creation of signal area masks
for nuclei and HCoV-OC43 FISH signals. (C) Enumeration of nuclei and HCoV-OC43 RNA FISH area in three random fields per condition. (D) Confirmation of HCoV-
OC43 FISH data with qRT-PCR for viral genomic (ORF1b) and subgenomic (nucleocapsid). Parallel plates were infected and treated similarly to those in A.
(Fig. 3C). Over five independent experiments, we obtained an average
EC50 of 0.024 ± 0.018 μM (mean± standard deviation) (Fig. 3D).
Importantly, since cytotoxicity (CC50 > 10 μM) was not observed in
Huh7 cells across the dose range measured in the assay
(10 μM–0.0015 μM) (Fig. 3B), the SI for this assay was>400.
3.4. Porcine deltacoronavirus is susceptible to the antiviral activity of RDV
The genetically diverse CoV family infects a wide variety of avian
and mammalian hosts. Of the four CoV genera, the deltacoronavirus
have the most divergent RNA dependent RNA polymerase (RdRp) as
compared to SARS- and MERS-CoV (67–69% amino acid similarity to
SARS- or MERS-CoV) (Fig. 4A). Interestingly, deltacoronavirus RdRp
naturally harbor a leucine at residue 483 which is associated with
partial resistance (i.e. up to a 5-fold shift in EC50) to RDV in MHV
(F476L) and SARS-CoV (F480L) at the homologous positions (Fig. 4A).
We mapped the percent amino acid identity for the CoVs described in
Fig. 4A to determine if variation was localized to one specific region or
functional domain (Fig. 4B). While there is variation across the entire
protein, there are regions of concentrated heterogeneity in between
motifs B (nucleotide binding) and C (SDD motif in the active site) and in
the C-terminal region of the thumb domain (Fig. 4B). Importantly, most
of the RdRp functional domains (A-G) as described by Xu et al., in 2003
for SARS-CoV (Fig. 4C) are highly conserved (i.e. 100% identity) (Xu
et al., 2003).
Given the divergence of the deltacoronavirus RdRp and the naturally
occurring putative resistance mutation, we sought to determine the
susceptibility of members of the deltacoronavirus genus to the antiviral
effect of RDV. Using porcine deltacoronavirus (PDCoV) as a model, we
first established an antiviral assay in the porcine kidney epithelial cell
line, LLC-PK1, which support robust PDCoV replication (Fig. 5A). En-
teric CoV (i.e. PDCoV, PEDV) require the addition of digestive enzymes
(i.e. trypsin, pancreatin) to culture medium for efficient replication and
CPE (Beall et al., 2016; Hu et al., 2015b). In LLC-PK1 cells with serum-
free medium and pancreatin, RDV did not diminish PDCoV replication
greater than 50% thus the EC50 could not be determined (Fig. 5B–D). To
ascertain whether PDCoV was naturally resistant to RDV or if the LLC-
PK1 cell harbored an unknown defect in a cellular process required for
antiviral activity (i.e. nucleotide uptake, metabolism, etc.), we per-
formed similar antiviral assays with HCoV-229E in LLC-PK1 cells
(Fig. 5E). Similar to PDCoV, RDV was not potent against HCoV-229E in
LLC-PK1 cells (EC50= 3.8 μM, Fig. 5F and G) yet the antiviral activity
of RDV against HCoV-229E in Huh7 cells in PDCoV assay medium (i.e.
serum free medium with trypsin) were similar to those in Fig. 3
(EC50= 0.02 μM, Fig. 5G). These data suggest LLC-PK1 cells are defi-
cient in a cellular process required for the antiviral activity of RDV.
Importantly, in Huh7 cells cultured in TPCK trypsin-containing and
serum-free media, (Fig. 5H), PDCoV replication was dose-dependently
reduced (Fig. 5I) with an EC50 value of 0.02 μM (Fig. J and K, a CC50
value > 10 μM and a SI > 500). All together with previous publica-
tions, these data demonstrate that a panel of CoV representing family-
wide genetic diversity in the RdRp are susceptible to the inhibition by
RDV.
4. Discussion
Effective broad-spectrum therapies are needed for the emerging
viral threats of today, like Ebola and MERS-CoV, as well as those that
have yet to emerge. There are multiple examples of novel CoV emer-
gence including all six human CoV, which are thought to have emerged
as zoonoses (Hu et al., 2015a; Huynh et al., 2012; Menachery et al.,
2016; Vijgen et al., 2005). Unlike SARS- and MERS-CoV, which are
known to cause more sporadic outbreaks, the other four human CoV are
endemic causing annual widespread morbidity in infants and the el-
derly, potentially requiring hospitalization. (Carman et al., 2018; Falsey
et al., 2002; Varghese et al., 2018). Although rare, endemic human CoV
like HCoV-229E and HCoV-OC43 can also cause severe respiratory
disease (pneumonia, ARDS, etc.) in subsets of patients, with presenta-
tion similar to SARS- and MERS-CoV (Falsey et al., 2002; Patrick et al.,
2006; Vassilara et al., 2018). Thus, the capacity for human CoV to cause
severe disease is not unique to emerging viruses like SARS- and MERS-
CoV. While there are no CoV specific antivirals approved for human
use, many approved therapies for other indications have been evaluated
against CoV in hopes of repurposing. The antimalarial, chloroquine,
reportedly has moderate antiviral activity in vitro against SARS-CoV
(IC50= 3 μM), MERS-CoV (IC50= 3–4 μM), HCoV-OC43
(IC50= 0.3 μM) and 229E (IC50= 3.3 μM) but failed to exert an anti-
viral effect against SARS-CoV in mice (Barnard et al., 2006; de Wilde
et al., 2014; Shen et al., 2016). Inhibition of viral protease has also been
evaluated with lopinavir, a protease inhibitor designed for human im-
munodeficiency virus, which like chloroquine exerts a moderate anti-
viral effect on CoV replication (EC50 values: MERS-CoV 8 μM, SARS-
CoV 17.1 μM, HCoV-229E 6.6 μM) (de Wilde et al., 2014). RDV is a
broad-spectrum antiviral drug with potent in vitro antiviral activity and
in vivo therapeutic efficacy against CoV (Agostini et al., 2018; Murphy
et al., 2018; Sheahan et al., 2017). However, the full breadth of activity
against CoV has yet to be determined. Previously, we demonstrated
antiviral activity of RDV against SARS-CoV and related zoonotic bat-
CoV (beta 2b), MERS-CoV, and related bat-CoV (beta 2c), HCoV-NL63
(alpha 1b), and MHV (beta 2a) (Agostini et al., 2018; Sheahan et al.,
2017). In addition, the parental nucleoside (GS-441524) of RDV (i.e.
the prodrug of GS-5734) has a reported EC50 of 0.7 μM against feline
infectious peritonitis virus (FIP, alpha 1a CoV) and could reverse lethal
disease in experimental infectious of cats (Murphy et al., 2018). Here,
we show that RDV has potent antiviral activity against HCoV-OC43,
HCoV-229E, and PDCoV which are in subgenera beta 2a, alpha 1b, and
Fig. 3. HCoV 229E antiviral assay. A) The antiviral activity of RDV against HCoV-229E was measured in a cytopathic effect-based assay in Huh7 cells by CellTiter-
Glo assay. Each dot represents the data from one well in a 96-well plate. The line is at the mean and error bars represent the standard deviation. B) Cytotoxicity of
RDV was measured via CellTiter-Glo assay. C) Percent inhibition and percent cytotoxicity from data in panel A and panel B to determine EC50 and CC50. Five
independent studies were performed (average EC50= 0.024 μM). Representative data from a single experiment is shown.
delta 4, respectively. While we have not yet tested a representative from
alpha 1a (e.g. PEDV) or gamma (e.g. avian infectious bronchitis virus,
AIBV), CoV members with similar RdRps, like HCoV-229E, have been
evaluated. The other outstanding subgenera yet to be evaluated is beta
2d, which is currently comprised of only bat-CoV (Lau et al., 2010).
Culture systems for beta 2d viruses are currently not available. Thus,
with this report, we demonstrate potent antiviral activity of RDV
against representatives capturing near family-wide CoV RdRp diversity
including deltacoronavirus which have the most divergent RdRp of
known CoV as compared to SARS- and MERS-CoV. These data suggest
that future emerging CoV may be similarly susceptible to the inhibition
by RDV.
The CoV RNA replication complex is comprised of multiple viral
proteins one of which, the viral RdRp, generates nascent genomic and
subgenomic viral RNAs. While the CoV RdRp is relatively conserved,
the amino acid percent similarity can vary from 67 to 100%. For
Fig. 4. Variation in CoV RdRp and susceptibility to RDV. (A) Dendrogram showing genetic relatedness of representative human and zoonotic CoV RdRp proteins.
Font color of virus name corresponds to natural host for virus shown above. Amino acid sequence alignment shows 483L RDV resistance mutation is naturally
occurring in deltacoronavirus (genotype 4). The percent similarity of each RdRp as compared to SARS-CoV and MERS-CoV is indicated in the heat map. (B) Variation
in CoV specific, fingers, palm and thumb domains of RdRp shown in % amino acid identity plot (top) and in the more detailed heat map showing % identity per
residue within the RdRp functional domains (A–G) and RDV resistance mutations identified in MHV (F476L, V553L) mapped. (C) Amino acid multiple sequence
alignments for each RdRp functional motif showing high conservation. Amino acid positions are noted in the multiple sequence alignment which corresponds to
positions above as well as in SARS-CoV RdRp (bold).
antiviral drugs that interact and interfere with RdRp function, variation
in amino acid sequence and resultant protein structure can have pro-
found effects on susceptibility. Lo et al. recently reported a correlation
between nucleotide interaction motifs “A” and “B” in the RdRp and
susceptibility to the antiviral activity of RDV (Lo et al., 2017). Motifs A
and B were highly conserved within virus families and generally cor-
related with RDV antiviral activity but for members of Flaviviridae (i.e.
West Nile virus EC50 =>30 μM, yellow fever virus EC50= 11 μM, tick
borne encephalitis virus EC50= 2.1 μM, hepatitis C virus
EC50= 4.1 μM), the potency of RDV was mixed even though motifs A
and B were for the most part highly conserved. Thus, other factors in
the RdRp structure or function likely mediate this discrepancy. Muta-
tions (F476L and V553L), identified through passage of MHV in the
presence of RDV, provide partial resistance to RDV antiviral activity
(i.e. 2.4-fold and 5-fold shift in EC50, respectively). Interestingly,
though MHV and SARS-CoV RdRp are 80% identical, resistance is
transferable to SARS-CoV via reverse genetic introduction of homo-
logous mutations (F480L and V557L) (Agostini et al., 2018). Here, we
show that PDCoV, a member of the deltacoronavirus genus, is exquisitely
sensitive to RDV despite naturally harboring a one of the two RdRp
resistance mutations identified in MHV. Without a reverse genetic
system for PDCoV, it is not possible to definitively determine if this
homologous mutation (483L) alters the antiviral effect of RDV on
PDCoV. In the very recent publication describing the SARS-CoV RdRp
structure, the authors suggest the F480L mutation, located in the fingers
domain contacting motif B, impacts active site dynamics related to
catalysis (Kirchdoerfer and Ward, 2019). Interestingly, Kirchdorfer and
Ward suggest the V557L (V553L in MHV) resistance mutation in the
SARS-CoV RdRp increases stringency of base pairing thereby increasing
polymerase fidelity allowing for better exclusion of RDV from the active
site (Kirchdoerfer and Ward, 2019). Future studies will focus on passage
of PDCoV for RDV resistance to determine if genetically divergent CoV
take similar or different paths towards acquiring RDV resistance.
Broad-spectrum approaches maximize the utility of antivirals with
proven efficacy against current epidemic strains as well as zoonotic
viruses that will likely seed future emergence. Here, we further describe
Fig. 5. Porcine deltacoronavirus is susceptible to the antiviral activity of RDV. A) Overview of the CPE-based antiviral assay for PDCoV in LLC-PK1 cells. (B)
Representative relative light units (RLU) raw data from one of four independent PDCoV assays in LLC-PK1 cells. C) Example cytoxicity data (RLU) measured via
CellTiter-Glo for RDV in LLC-PK1 cells. (D) RDV EC50 and CC50 curves for PDCoV in LLC-PK1 cells. (E) Overview of RDV CPE-based antiviral assays in either LLC-PK1
or Huh7 cells for HCoV-229E using PDCoV media conditions. (F) RLU raw data for HCoV-229E in LLC-PK1 or Huh7 cells using media formulations for PDCoV. (G)
EC50 curves for raw data shown in F. (H) Overview of RDV CPE-based antiviral assay for PDCoV in Huh7 cells. (I) Representative RLU raw data one of five
independent PDCoV assays in Huh7 cells. (J) Example cytoxicity data (RLU) measured via CellTiter-Glo for RDV in Huh7 cells for assay described in “H”. (K)
Representative RDV EC50 and CC50 curves for PDCoV in Huh7 cells. For B, C, F, I and J, each dot represents the data from one well in a 96-well plate. The line is at the
mean and error bars represent the standard deviation.
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the breadth of RDV antiviral activity against both human and zoonotic 
CoV. We found that RDV had decreased potency against 229E and 
PDCoV in the porcine kidney cell line, LLC-PK1, although these viruses 
were similarly sensitive in the human hepatoma cell, Huh7. Although 
different from RDV, normal uptake and metabolism has been reported 
for the nucleoside analog lamivudine (i.e. 3 TC) in LLC-PK1 (Leung and 
Bendayan, 2001). Interestingly, uptake and the antiviral activity of ri-
bavirin, another nucleoside analog, was reported to vary significantly 
among human liver cell lines, which was directly correlated with an-
tiviral activity against poliovirus indicating that variation in small 
molecule uptake/transport can impact antiviral efficacy (Ibarra and 
Pfeiffer, 2009). While RDV does have altered metabolism in mice due to 
the circulating serum carboxylesterase 1c (Ces1c) that is absent in hu-
mans (Sheahan et al., 2017), it is potently antiviral against MHV in 
mouse DBT cells (Agostini et al., 2018). Therefore, the Ces1c metabo-
lism issue with RDV is specific to the mouse in vivo system. Although it 
is likely that LLC-PK1 cells are deficient in a cellular process required 
for the antiviral activity of RDV, without further testing in other porcine 
cell lines, it is not possible to ascertain whether this is cell line specific 
or species specific or to speculate about the potential efficacy against 
PDCoV in pigs. Here, we have focused our efforts on developing in vitro 
assays for human and zoonotic CoV but animal models exist for HCoV-
229E and OC43 as well as PDCoV within which in vivo efficacy could be 
evaluated (Jung et al., 2015; Lassnig et al., 2005; St-Jean et al., 2004). 
Given that we have demonstrated antiviral activity against a panel of 
CoVs with the great RdRp diversity, RDV may too be efficacious against 
future emerging CoV as long as they fall within the spectrum of known 
genetic diversity. To prepare for the potential of drug resistance to 
single therapies, multiple novel broad-spectrum antiviral strategies are 
needed. Moreover, with desired safety profiles, combination broad-
spectrum antiviral therapies with disparate mechanisms of action may 
be more effective at treating emerging viral syndromes in parallel prior 
to etiological agent identification. If available, new antiviral therapies 
would markedly expand the current treatment options available to 
clinicians. The current front-line agents treating emerging viral epi-
demics (i.e. ribavirin, interferon, lopinavir/ritonavir, and corticoster-
oids) often do not improve outcomes over supportive care (Zumla et al., 
2016). Therefore, our studies provide further evidence of the antiviral 
activity of RDV against endemic, epidemic, and zoonotic CoV, which 
may be useful in treating patients with severe endemic CoV infections, 
MERS-CoV patients or emerging CoV diseases in the future provided 
that the drug safety profile is proven to be compatible with its use in the 
affected patient populations.
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